The Effect of Primary Cesarean Section Prevention on Maternal and Neonatal Outcomes
The study aimed to examine the effect of prolonging the second stage of labor on the rate of Cesarean section (CS), maternal and neonatal outcomes.
The study compared 2 time periods. The first time period was between May 2011 until April 2014 when a prolonged second stage in nulliparous women was considered three hours with regional anesthesia or two hours if no such anesthesia was provided. Second stage arrest was defined in multiparous women after two hours with regional anesthesia or one hour without it. The second time period was between May 2014 until April 2017, allowed nulliparous and multiparous women to continue the second stage of labor an additional one hour before diagnosing second-stage arrest. Singleton deliveries at or beyond 37 weeks' gestation were initially considered for eligibility.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The study aimed to examine the effect of prolonging the second stage of labor on the rate of Cesarean section (CS), maternal and neonatal outcomes.
The study compared 2 time periods. The first time period was between May 2011 until April 2014 when a prolonged second stage in nulliparous women was considered three hours with regional anesthesia or two hours if no such anesthesia was provided. Second stage arrest was defined in multiparous women after two hours with regional anesthesia or one hour without it. The second time period was between May 2014 until April 2017, allowed nulliparous and multiparous women to continue the second stage of labor an additional one hour before diagnosing second-stage arrest. Singleton deliveries at or beyond 37 weeks' gestation were initially considered for eligibility.
The rate of CS, operative vaginal deliveries, 3rd and 4th degree lacerations, postpartum hemorrhage, arterial cord PH below 7 and admissions to the neonatal intensive care unit (NICU).
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Haifa, Israel
- Rambam Health Care Campus
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
1. Singleton deliveries at or beyond 37 weeks' gestation.
Exclusion Criteria:
- Non-vertex presentation.
- Trial of labor after CS.
- High risk pregnancy (multiple gestation, preeclampsia, diabetes mellitus, intrauterine growth restriction).
- Known fetal anomalies and intrauterine fetal demise.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Prolonged second stage of labor
Women with prolonged second stage of labor as specified before.
|
To examine the effect of prolonging the second stage of labor on the rate of cesarean delivery, maternal and neonatal outcomes
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The rate of primary CS.
Prazo: Between 2011 and 2017.
|
The rate of primary CS in percentage of the total participants.
|
Between 2011 and 2017.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The rate of operative vaginal delivery.
Prazo: Between 2011 and 2017.
|
The rate of operative vaginal delivery in percentage of the total participants.
|
Between 2011 and 2017.
|
|
Post-partum hemorrhage.
Prazo: Between 2011 and 2017.
|
Post-partum hemorrhage as estimated in liters.
|
Between 2011 and 2017.
|
|
The need for blood transfusion.
Prazo: Between 2011 and 2017.
|
Number and type of blood products required post-partum and calculation of the number of patients that required blood products out of the total number of participants in percentage.
|
Between 2011 and 2017.
|
|
Third-and fourth-degree laceration rate.
Prazo: Between 2011 and 2017.
|
Third-and fourth-degree laceration rate of the total number of participants.
|
Between 2011 and 2017.
|
|
Chorioamnionitis rate.
Prazo: Between 2011 and 2017.
|
Chorioamnionitis rate in percentage of the total participants.
|
Between 2011 and 2017.
|
|
Admission to the NICU.
Prazo: Between 2011 and 2017.
|
Admission to the NICU in percentage of the total participants.
|
Between 2011 and 2017.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Kamel Mattar, MD, Principal Investigator
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- 0258-17-RMB
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .